Allergan faced intense criticism over its attempt to protect Restasis patents through sovereign immunity, and now an appeals court has ruled the strategy won't fly. The U.S. Court of Appeals for the ...

When Allergan transferred six Restasis patents to the Saint Regis Mohawk tribe in 2017 in a bid to shield the dry-eye treatment from generic competition, it was widely maligned by everyone from ...

Why are Americans, both as patients and taxpayers, paying billions of dollars for a drug whose efficacy is so questionable that it's not approved in the European Union, Australia or New Zealand?

Restasis is a brand-name eye drop that’s prescribed for chronic dry eye. The medication is available in single-use and multiuse vials. Restasis is a type of immunosuppressant. Restasis is approved by ...

TEVA's generic Restasis was approved in Canada last week. AGN's Restasis receives about 4% of its revenue from Canada. Q1 2018 Restasis revenue fell 15% Y/Y. Teva's generic Restasis will provide ...

A patent to a blockbuster drug like Restasis, which has over $1.4 billion in annual sales in the United States, deserves greater consideration than a once sentence disposition that simply says: ...